| Amy B Ziegler, NP | |
|
300 Pasteur Dr, Stanford, CA 94305-2200 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Amy B Ziegler |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 300 Pasteur Dr, Stanford, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023109162 | NPI | - | NPPES |
| 36014500 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 20584 (California) | Secondary |
| 363L00000X | Nurse Practitioner | 20584 (California) | Primary |
| Entity Name | Northbay Healthcare Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821147786 PECOS PAC ID: 0042122244 Enrollment ID: O20031105000409 |
News Archive
The Wellmark Blue Cross/Blue Shield vice president faced dozens of angry customers and tried to explain why the health insurer wants to increase their premiums by 9.4 percent. ... Barbed questions flew throughout the hearing before the state insurance commissioner, who will decide whether to grant Wellmark's proposed increase for 86,000 Iowans who buy their own insurance policies.
The genetic factors that cause increased sleep problems during times of stress seem to be the same as those that make people with intrusive and ruminative thoughts have a higher prevalence of insomnia, according to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.
AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."
› Verified 4 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
The Wellmark Blue Cross/Blue Shield vice president faced dozens of angry customers and tried to explain why the health insurer wants to increase their premiums by 9.4 percent. ... Barbed questions flew throughout the hearing before the state insurance commissioner, who will decide whether to grant Wellmark's proposed increase for 86,000 Iowans who buy their own insurance policies.
The genetic factors that cause increased sleep problems during times of stress seem to be the same as those that make people with intrusive and ruminative thoughts have a higher prevalence of insomnia, according to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.
AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."
› Verified 4 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
The Wellmark Blue Cross/Blue Shield vice president faced dozens of angry customers and tried to explain why the health insurer wants to increase their premiums by 9.4 percent. ... Barbed questions flew throughout the hearing before the state insurance commissioner, who will decide whether to grant Wellmark's proposed increase for 86,000 Iowans who buy their own insurance policies.
The genetic factors that cause increased sleep problems during times of stress seem to be the same as those that make people with intrusive and ruminative thoughts have a higher prevalence of insomnia, according to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.
AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy B Ziegler, NP 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 | Amy B Ziegler, NP 300 Pasteur Dr, Stanford, CA 94305-2200 Ph: (650) 723-4000 |
News Archive
The Wellmark Blue Cross/Blue Shield vice president faced dozens of angry customers and tried to explain why the health insurer wants to increase their premiums by 9.4 percent. ... Barbed questions flew throughout the hearing before the state insurance commissioner, who will decide whether to grant Wellmark's proposed increase for 86,000 Iowans who buy their own insurance policies.
The genetic factors that cause increased sleep problems during times of stress seem to be the same as those that make people with intrusive and ruminative thoughts have a higher prevalence of insomnia, according to a research abstract that will be presented on Tuesday, June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.
AIDS Healthcare Foundation (AHF) today called for a top to bottom shake-up of the management at the Food and Drug Administration as well as a Congressional investigation following the publication of a Washington Post news article (1/31/12) that reported, "…the Food and Drug Administration secretly monitored the personal e-mail of a group of its own scientists and doctors after they warned Congress that the agency was approving medical devices that they believed posed unacceptable risks to patients."
› Verified 4 days ago
Angie Dee Murkins, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Gloria Le Choi, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Mrs. Joi Mei Soucy, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Olinda Su Mar, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-723-4000 | |
Laura Lynne Asaro, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 875 Blake Wilbur Dr, Clinic D, Stanford, CA 94305 Phone: 650-723-6197 | |
Nancy S. Brook, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-498-7103 | |
Mr. Richard Quitevis, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 Pasteur Dr, Stanford, CA 94305 Phone: 650-724-2906 |